In this article, we break down the Top 5 Best Biotech Penny Stocks to Buy This June. For investors looking for the complete list, you can explore our full report on the Top 10 Best Biotech Penny Stocks to Buy This June.
5. Geron Corporation (NASDAQ:GERN)
Geron Corporation enters the top five because it has something many biotech penny stocks do not have: real product revenue. Trading around $1.25 with a market capitalization of roughly $800 million, GERN is no longer just a speculative clinical-stage story. It has an approved product in RYTELO, and that changes the way investors should look at the stock.
RYTELO generated $51.8 million in net product revenue in Q1 2026, up 8% sequentially. That is important because it shows that Geron is not simply waiting for a future binary event. It already has a commercial asset in the market. In biotech, the moment a company transitions from approval to revenue generation, investors get more concrete numbers to evaluate. Sales growth, launch trajectory, market adoption, expenses, and guidance become the new story.
The company also reiterated 2026 revenue guidance of $220 million to $240 million. That gives investors a measurable target. For a biotech penny stock, having revenue guidance is a major distinction. Many low-priced biotech companies are still years away from meaningful sales, while Geron is already being judged on product performance. That makes it one of the more serious names on this June list of best biotech penny stocks to buy and watch.
The attraction is clear. GERN combines a low stock price with an approved drug and a real revenue base. That is the kind of setup that often gets overlooked by casual penny-stock traders who only chase clinical headlines. But professional investors know that revenue can matter more than hype, especially in a market where funding conditions are tighter and speculative biotech names are being filtered more aggressively.
Still, Geron has to prove that revenue growth can move fast enough toward profitability. Expenses matter. Commercial execution matters. Market penetration matters. If RYTELO sales continue to build, the stock could earn a stronger valuation. If growth slows or costs remain too heavy, investors may stay cautious despite the approved-product story.
That is why Geron deserves the No. 5 spot. It is one of the stronger “cheap stock but real product” stories in the biotech penny stock universe. It may not have the wildest speculative setup, but it has something more valuable for serious investors: actual sales that can be tracked quarter after quarter.
Click next to see the following stock...
